Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

21.08USD
10:50pm IST
Change (% chg)

$0.08 (+0.38%)
Prev Close
$21.00
Open
$20.61
Day's High
$21.38
Day's Low
$20.60
Volume
1,302,914
Avg. Vol
2,240,117
52-wk High
$39.59
52-wk Low
$16.64

Summary

Name Age Since Current Position

Robert Coury

58 2016 Non-Executive Chairman of the Board

Rajiv Malik

58 2016 President, Executive Director

Heather Bresch

49 2016 Chief Executive Officer, Executive Director

Mark Parrish

63 2017 Lead Independent Non-Executive Vice Chairman of the Board

Kenneth Parks

55 2016 Chief Financial Officer

Anthony Mauro

45 2016 Chief Commercial Officer

Robert Cindrich

75 2016 Non-Executive Independent Director

JoEllen Dillon

55 2016 Non-Executive Independent Director

Neil Dimick

69 2016 Non-Executive Independent Director

Melina Higgins

51 2016 Non-Executive Independent Director

Harry Korman

61 2018 Non-Executive Independent Director

Richard Mark

66 2019 Non-Executive Independent Director

Pauline van der Meer Mohr

59 2018 Non-Executive Independent Director

Randall Vanderveen

68 2016 Non-Executive Independent Director

Sjoerd Vollebregt

64 2017 Non-Executive Independent Director

Biographies

Name Description

Robert Coury

Mr. Robert J. Coury has served as Non-Executive Chairman of the Board of Mylan N.V. since June 3, 2016. Under his visionary leadership, Mylan has transformed from the third largest generics pharmaceutical company in the U.S. into one of the largest pharmaceutical companies in the world in terms of revenue, earning spots in both the S&P 500 and, prior to the Company’s reincorporation outside of the U.S. in 2015, the Fortune 500. Mr. Coury was first elected to the Mylan Board in February 2002, having served since 1995 as a strategic advisor to the Company. He became the Mylan Board’s Vice Chairman shortly after his election and served as CEO from September 2002 until January 2012, and as Executive Chairman from 2012 until he became Chairman as a director who is not an employee of the Company or Mylan Inc. (a “Non-Employee Director”, with all such directors being the “Non-Employee Directors”) in June 2016. Since 2007, Mr. Coury has led the Company through a series of transactions totaling approximately $25 billion, which transformed Mylan into a global powerhouse within the highly competitive pharmaceutical industry, with a global workforce of over 35,000 and products sold in more than 165 countries. In 2007, Mylan purchased India-based Matrix Laboratories Limited, a major producer of active pharmaceutical ingredients, and the generics and specialty pharmaceuticals business of Europe-based Merck KGaA. Subsequent acquisitions under Mr. Coury’s leadership further expanded the Company into new therapeutic categories and greatly enhanced its geographic and commercial footprint. In 2010, Mylan acquired Bioniche Pharma, a global injectables business in Ireland; in 2013, Mylan acquired India-based Agila Specialties, a global injectables company; and in 2015, Mylan acquired the EPD Business and Famy Care Ltd.’s women’s healthcare businesses. Board Committees: Executive (Chair). BS industrial engineering from University of Pittsburgh 1984.

Rajiv Malik

Mr. Rajiv Malik has served as President, Executive Director of Mylan N.V. since 2016. Mr. Malik has served as Mylan’s President since January 1, 2012 and has more than 35 years of experience in the pharmaceutical industry. Previously, Mr. Malik held various senior roles at Mylan, including Executive Vice President and Chief Operating Officer from July 2009 to December 2012, and Head of Global Technical Operations from January 2007 to July 2009. Mr. Malik has been integral in developing the strategies for the company’s acquisitions and, more importantly, in the execution and integration of acquisitions, specifically the generics business of Merck KgaA; the injectables business of Bioniche; Agila Specialties, a global injectables company; the EPD Business; Famy Care Ltd.’s women’s healthcare businesses; Meda, a leading international specialty pharmaceutical company that sells prescription and over-the-counter products; and most recently, the non-sterile, topicals-focused business of Renaissance Acquisition Holdings, LLC. Mr. Malik oversees the day-to-day operations of the Company which includes commercial, scientific affairs, manufacturing, supply chain and quality as well as business development and information technology. Mr. Malik has been instrumental in expanding and optimizing Mylan’s product portfolio, leveraging Mylan’s global research and development capabilities and expanding Mylan’s presence in emerging markets. Previously, he served as chief executive officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as head of global development and registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz GmbH, Mr. Malik was head of global regulatory affairs and head of pharma research for Ranbaxy from October 1999 to September 2003. Board Committees: Science and Technology. Masters degree from Punjab Agricultural University, Ludhiana.

Heather Bresch

Ms. Heather M. Bresch has served as Chief Executive Officer, Executive Director of Mylan N.V. since 2016. Within the Company, she was Chief Executive Officer, Director between January 1, 2012 and 2016, President, Director between March 1, 2011 and January 1, 2012, President between July 29, 2009 and March 1, 2011, Chief Operating Officer, Executive Vice President between October 2007 and July 29, 2009, and Head - North American Operations between January 31, 2007 and October 2007. Board Committees: Science and Technology. Throughout her 27-year career with Mylan, she has held roles of increasing responsibility in more than 15 functional areas. As CEO, Ms. Bresch has been leading the next chapter of Mylan’s growth and performance, pursuing a strategy that has produced a sustainable organization that is making great strides in its mission of delivering better health for a better world by providing 7 billion people access to high quality medicine. In continuing to execute on this strategy, Ms. Bresch is focused on further diversifying the Company in terms of products, markets and channels, a process proven to expand access and generate durable cash flows that can be reinvested to further differentiate Mylan and position it to support the transformation of outdated healthcare systems. Ms. Bresch is a frequent speaker on issues such as affordable healthcare and global competitiveness and has testified before the U.S. Congress and U.S. Food and Drug Administration (“FDA”) on issues related to access to medicine. Ms. Bresch is the pharmaceutical industry’s first female chief executive officer of a Fortune 500 company and, each year since 2012, has been named by Fortune magazine as one of its “50 Most Powerful Women.” She graduated from West Virginia University.

Mark Parrish

Mr. Mark W. Parrish has served as Lead Independent Non-Executive Vice Chairman of the Board of Mylan N.V. since August 2017. Mr. Parrish has served as the Lead Independent Director and Vice Chairman of Mylan’s Board since August 2017. Within the Company, he was Non-Executive Independent Director between 2016 and August 2017, and Independent Director between September 1, 2009 and 2016. He has served as chief executive officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, since 2008 and served as chairman from 2008 to 2013. Since January 2013, Mr. Parrish also has served on the board of directors of Omnicell, Inc., a company that specializes in healthcare technology. Mr. Parrish also serves on the boards of directors of Silvergate Pharmaceuticals, a private company that develops and commercializes pediatric medications, and GSMS, a private company that specializes in meeting unique labeling and sizing needs for its customers and pharmaceutical packaging, serialization and distribution. From 2001 to 2007, Mr. Parrish held management roles of increasing responsibility with Cardinal Health Inc. and its affiliates, including chief executive officer of Healthcare Supply Chain Services for Cardinal from 2006 to 2007. Mr. Parrish also serves as president of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies, and as senior adviser to Frazier Healthcare Ventures, a healthcare oriented growth equity firm. His qualifications to serve on Mylan’s Board include, among others, his experience as a chief executive officer; his knowledge and experience regarding issues, risks and opportunities in the global healthcare industry; and his knowledge and expertise regarding compliance. Board Committees: Audit; Compliance (Chair); Executive; Governance and Nominating; Risk Oversight. BA from University of California, Berkeley.

Kenneth Parks

Mr. Kenneth Scott (Ken) Parks has served as Chief Financial Officer of Mylan N.V. since June 6, 2016. Ken Parks is Mylan’s chief financial officer and is responsible for all of the company’s global finance functions, including accounting and control, financial planning and analysis, investor relations, treasury and tax. He also leads Mylan’s Global Integrated Services organization, which centralizes the management of transaction-intensive Finance, Human Relations, IT and other activities to drive scale, efficiency and consistency. In addition, he heads up Global Data and Strategic Analytics, which provides actionable insights to the company’s leaders as well as analytics solutions to the broader business. Parks joined Mylan in June 2016 from WESCO International, a leading provider of electrical, industrial and communication products, where he led all aspects of the finance function. Prior to WESCO, Parks spent the majority of his career at United Technologies Corporation (UTC) in a variety of U.S. and international finance roles. He most recently served as the company’s vice president, Finance, for its $7 billion UTC Fire & Security division. Prior to that, he led UTC’s Investor Relations function. In addition, Parks also held several roles at UTC's $10 billion Carrier Corporation division, including director, Financial Planning and Analysis (FP&A), and vice president of Operations Finance. He spent four years in Paris as Controller and then as director, FP&A, for Carrier's European, Middle East and Africa operations. Parks spent his early years at UTC in auditing, financial reporting and controllership. He began his career at the accounting firm Coopers & Lybrand, where he became a certified public accountant. Parks earned a Bachelor of Science degree in accounting from University of Tulsa.

Anthony Mauro

Mr. Anthony R. (Tony) Mauro has served as Chief Commercial Officer of Mylan N.V. since January 4, 2016. Prior to that date, Mr. Mauro served as President, North America of Mylan since January 1, 2012. He served as President of Mylan Pharmaceuticals Inc. from 2009 through February 2013. In his 21 years at Mylan, Mr. Mauro has held roles of increasing responsibility, including Chief Operating Officer for Mylan Pharmaceuticals ULC in Canada and Vice President of Strategic Development, North America, and Vice President of Sales, North America for Mylan. Mr. Parks has served as Chief Financial Officer since June 2016. Mr. Parks previously served as chief financial officer for WESCO International (“WESCO”), a leading provider of electrical, industrial, and communication products, from June 2012 to May 2016, where he led all aspects of the finance function. He holds a Bachelors degree in Business Administration from West Virginia University, and a Masters degree in Business Administration from West Virginia University.

Robert Cindrich

Hon. Robert J. Cindrich has served as Non-Executive Independent Director of Mylan N.V. since 2016. He was Independent Director of the Company between March 1, 2011 and 2016. He has been serving as president of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance and business strategies. From October 1, 2013, through January 31, 2014, he served as interim general counsel for United States Steel Corporation (“U.S. Steel”) (NYSE: X), an integrated steel producer of flat-rolled and tubular products. He joined Schnader Harrison Segal & Lewis (“Schnader”), a law firm, as legal counsel in April 2013 and took a temporary leave of absence on October 1, 2013, to join U.S. Steel as interim general counsel, returning to Schnader after his time there and remaining until December 2017. In May 2012, he joined the board of directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012, Judge Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (“UPMC”), an integrated global health enterprise. From 2004 through 2010, Judge Cindrich was a senior vice president and the chief legal officer of UPMC. From 1994 through January 2004, he served as a judge on the U.S. District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney. Board Committees: Compliance; Governance and Nominating; Risk Oversight; Science and Technology. He graduated from the University of Pittsburgh.

JoEllen Dillon

Ms. JoEllen Lyons Dillon has served as Non-Executive Independent Director of Mylan N.V. since 2016. She was Independent Director of the Company between 2014 and 2016. Ms. Dillon served most recently as chief legal officer and corporate secretary of The ExOne Company (“ExOne”) (NASDAQ: XONE), a global provider of three-dimensional printing machines, from March 2013 to August 2017, and as executive vice president from December 2014 to August 2017. Previously, she was a legal consultant on ExOne’s initial public offering. Prior to that, Ms. Dillon was a partner with Reed Smith LLP, a law firm, from 2002 until 2011. She previously had been at the law firm Buchanan Ingersoll & Rooney PC from 1988 until 2002, where she became a partner in 1997. Ms. Dillon is a member of the board of trustees of the Allegheny District chapter of the National Multiple Sclerosis Society and has previously served as chair and audit committee chair. Ms. Dillon’s qualifications to serve on Mylan’s Board include, among others, her knowledge and expertise regarding legal and regulatory matters, financial matters, compliance, corporate governance, public company oversight and international business and strategy. Board Committees: Audit; Compensation (Chair); Executive; Governance and Nominating (Chair)

Neil Dimick

Mr. Neil F. Dimick, CPA, has served as Non-Executive Independent Director of Mylan N.V. since 2016. He was Independent Director of the Company between 2005 and 2016, Currently retired, Mr. Dimick previously served as executive vice president and chief financial officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was senior executive vice president and chief financial officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that, Mr. Dimick served as a partner with Deloitte & Touche LLP (“Deloitte”) for eight years. Mr. Dimick also serves on the board of directors of Resources Connection, Inc. (NASDAQ: RECN). Mr. Dimick also served on the boards of directors of WebMD Health Corp. from 2005 to September 2017, at which time it was purchased by Internet Brands, a portfolio company of investment funds affiliated with Kohlberg Kravis Roberts & Co., LP; Alliance HealthCare Services, Inc. from 2002 to August 2017, at which time it was purchased by Tahoe Investment Group Co., Ltd.; and Thoratec Corporation from 2003 to October 2015, at which time it was purchased by St. Jude Medical, Inc. Mr. Dimick’s qualifications to serve on Mylan’s Board include, among others, his experience and expertise regarding accounting, finance, the healthcare industry, international business, corporate governance, public company management, oversight and strategy, and international business transactions. Board Committees: Audit (Chair); Executive; Finance; Risk Oversight. BS in Accounting from Brigham Young University.

Melina Higgins

Ms. Melina E. Higgins has served as Non-Executive Independent Director of Mylan N.V. since 2016. Currently retired, She served as Independent Director of the Company between February 11, 2013 and 2016. Ms. Higgins held senior roles of increasing responsibility at The Goldman Sachs Group, Inc. (NYSE: GS), a global investment banking, securities and investment management firm, including partner and managing director, during her nearly 20-year career at the firm from 1989 to 1992 and 1994 to 2010. During her tenure there, Ms. Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas and as co-chairperson of the Investment Advisory Committee for GS Mezzanine Partners funds, which managed over $30 billion of assets and were global leaders in their industry. Ms. Higgins also is a member of the Women’s Leadership Board of Harvard University’s John F. Kennedy School of Government. In September 2013, Ms. Higgins joined the board of directors of Genworth Financial Inc. (NYSE: GNW), an insurance company. In January 2016, Ms. Higgins became non-executive chairman of Antares Midco Inc., a private company that provides financing solutions for middle-market, private equity-backed transactions. Ms. Higgins’ qualifications to serve on Mylan’s Board include, among others, her experience and expertise in finance, capital markets, international business and strategy, and international business transactions. Board Committees: Audit; Compensation; Finance (Chair). BA in Economics from Colgate University. MBA from Harvard University.

Harry Korman

Mr. Harry A. Korman serves as Non-Executive Independent Director of Mylan N.V. since 2018. Board Committees: Compliance; Risk Oversight (Chair); Science and Technology. He held senior executive roles of increasing responsibility at Mylan Inc. and its subsidiaries from 1996 until July 2014. He served as Mylan Inc.’s global Chief Operating Officer from January 2012 until July 2014, after which he served in a consultant role with Mylan Inc. for one year. Prior to his service as Chief Operating Officer, he was the President, North America of Mylan Inc. commencing in October 2007. He served as President of Mylan Pharmaceuticals Inc. from February 2005 to December 2009. During his time as an executive at Mylan, Mr. Korman was instrumental in identifying, evaluating and executing on significant commercial and business development opportunities in the United States and other countries, including the expansion of Mylan’s global generics businesses around the world, among many other important contributions to the Company and its stakeholders. He joined Mylan in 1996 after the Company’s acquisition of UDL Laboratories, Inc. (n/k/a Mylan Institutional Inc.), and served as its president, among other prior responsibilities. He served as a past director and vice chairman of the Generic Pharmaceutical Association, now known as the Association for Accessible Medicines. He also previously served as a director and vice chairman of the HDMA Foundation, which serves the healthcare industry by providing research and education focused on healthcare supply issues. His qualifications to serve on Mylan’s Board include, among others, his extensive industry and leadership experience, his knowledge of healthcare systems and the U.S. and global commercial markets, and his leadership experience in the areas of global strategy, risk oversight, sales and marketing, commercial operations, supply chain and business development, among other areas relevant and important to Mylan’s global business.

Richard Mark

Mr. Richard Mark, CPA, has served as Non-Executive Independent Director of Mylan N.V. since 2019. Mr. Mark currently serves on the board of directors of Goldman Sachs Middle Market Lending Corp., chairing its Audit Committee as an audit committee financial expert and serving on its Compliance, Audit, Governance and Nominating, and Contract Review committees. He previously served as a partner with Deloitte and Touche from June 2002 to May 2015, most recently leading the advisory corporate development function. Prior to joining Deloitte, Mr. Mark held various positions with Arthur Andersen & Co., including audit partner. Mr. Mark also served from July 2015 until August 2016 as Chairman of the Board of Directors and as a member of the Audit Committee of Katy Industries, Inc., a manufacturer, importer and distributor of commercial cleaning and consumer storage products. He also served on the board of directors of Cadence Health from 1993 to its acquisition by Northwestern Memorial Healthcare (“Northwestern”) in September 2014. Following the acquisition of Cadence Health, Mr. Mark was a director of Northwestern from September 2014 to August 2015, serving on its Executive and Nominating and Governance committees. Mr. Mark currently serves as a director of Almost Home Kids, a not-for-profit corporation affiliated with Lurie Children’s Hospital of Chicago, which provides transitional care to children with complicated health needs, training for their families and respite care. Mr. Mark’s qualifications to serve on Mylan’s Board include, among others, his experience and expertise regarding finance, the healthcare industry, global business experience, corporate governance, public company management, risk oversight and strategy, and international M&A.

Pauline van der Meer Mohr

Ms. Pauline van der Meer Mohr has served as Non-Executive Independent Director of Mylan N.V. since 2018. Board Committees: Compensation; Risk Oversight. Ms. van der Meer Mohr is currently an independent non-executive director of HSBC Holdings plc (LON: HSBA), chairing that company’s Group Remuneration Committee and serving as a member of its Group Risk Committee and the Nomination & Corporate Governance Committee. She also is a member of the supervisory boards of Royal DSM N.V. (AMS: DSM), currently serving as Deputy Chair, chairing its Remuneration Committee and serving on its Nomination Committee and EY Netherlands LLP, currently serving as Chair. Ms. van der Meer Mohr also serves as the Chair of the Dutch Corporate Governance Code Monitoring Committee. In addition, Ms. van der Meer Mohr recently served on the supervisory board of ASML Holding N.V. (NASDAQ and AMS: ASML) until April 2018, and as president of the Executive Board of Erasmus University in Rotterdam from 2010 to 2016. Ms. van der Meer Mohr began her career in the legal profession and previously held several legal and management positions within Royal Dutch Shell Group from 1989 to 2004. In 2004, she was appointed group human resources director at TNT N.V. before becoming senior executive vice president and head of group human resources at ABN AMRO NV in 2006. She served as a member of the Dutch Banking Code Monitoring Commission in the Netherlands from 2010 to 2013, and began her own human capital consulting firm in 2008. Ms. Van der Meer Mohr’s qualifications to serve on Mylan’s Board include, among others, her experience and expertise regarding corporate governance, finance, public company oversight outside of the U.S., legal and regulatory matters, human resources and executive compensation, risk management and oversight, corporate social responsibility and governance and oversight experience with respect to Dutch companies.

Randall Vanderveen

Dr. Randall (Pete) L. Vanderveen, Ph.D., has served as Non-Executive Independent Director of Mylan N.V. since 2016. He served as Independent Director of the Company between March 1, 2002 and 2016. Currently retired, Dr. Vanderveen most recently was Professor of Pharmaceutical Policy and Economics, Senior Adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, Director of the Margaret and John Biles Center for Leadership, and Senior Adviser to the Dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, California from 2015 to August 2017. Dr. Vanderveen previously served as Dean, Professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015, where he was named “Outstanding Pharmacy Dean in the Nation” in 2013 by the American Pharmacist Association. From 1998 to 2005, he served as Dean and Professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was Assistant Dean at Oregon State University from 1988 to 1998. Dr. Vanderveen has an extensive pharmaceutical and academic background. In addition, Dr. Vanderveen has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities and management of Mylan, among other matters. Dr. Vanderveen’s qualifications to serve on Mylan’s Board include, among others, his experience and expertise regarding the healthcare industry, pharmaceuticals and pharmacy practice, public healthcare policy and economics, and scientific matters. Board Committees: Compliance; Science and Technology (Chair). Bachelor of Science Pharmacy Purdue University 1974; Master of Science Purdue University 1976; PhD Michigan State University 1987.

Sjoerd Vollebregt

Mr. Sjoerd S. Vollebregt has served as Non-Executive Independent Director of Mylan N.V. since June 22, 2017. Mr. Vollebregt has been chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam listed company that operates in property development, residential building, non-residential building, roads and civil engineering, since 2015; chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris listed company, that develops solar arrays, satellite instruments and structures for launchers, since 2015; and chairman of the Economic Development Board Drecht Cities, a strategic collaboration between business, education and government in Drecht Cities, Netherlands, since December 2016. Mr. Vollebregt had served as chairman of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014, which was an Amsterdam Stock Exchange-listed industrial group until 2008, consisting of a global provider of knowledge-based maintenance, modification and asset integrity products and services, food and textile equipment manufacturer and chief executive officer of Fokker Technologies Group B.V., an aerospace company and a Stork B.V. subsidiary from 2010 to 2014. Previously, Mr. Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016, and has held various other senior positions at Excel plc, Ocean plc, Intexo Holding and Royal Van Ommeren. His qualifications to serve on Mylan’s Board include, among others, his experience as a chief executive officer; his experience and expertise in public company management outside of the U.S. and strategy; his experience and expertise in manufacturing, supply chain, and technology, as well as international business transactions; and his governance and oversight experience with respect to Dutch companies. Board Committees: Compliance; Finance; Governance and Nominating. Economics degree from Erasmus Universiteit Rotterdam.

Basic Compensation

Name Fiscal Year Total

Robert Coury

1,800,000

Rajiv Malik

8,742,130

Heather Bresch

12,744,400

Mark Parrish

468,789

Kenneth Parks

3,346,020

Anthony Mauro

4,197,010

Robert Cindrich

358,789

JoEllen Dillon

405,039

Neil Dimick

391,289

Melina Higgins

365,039

Harry Korman

285,019

Richard Mark

--

Pauline van der Meer Mohr

280,019

Randall Vanderveen

335,039

Sjoerd Vollebregt

345,039
As Of  31 Dec 2018

Options Compensation